Skip to main content
Log in

Selective activation of β3-adrenoceptors by octopamine: comparative studies in mammalian fat cells

  • Original article
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

Numerous synthetic agonists selectively stimulate β3-adrenoceptors (ARs). The endogenous catecholamines, noradrenaline and adrenaline, however, stimulate all the β-AR subtypes, and no selective physiological agonist for β3-ARs has been described so far. The aim of this study was to investigate whether any naturally occurring amine can stimulate selectively β3-ARs. Since activation of lipolysis is a well-known β-adrenergic function, the efficacy and potency of various biogenic amines were compared with those of noradrenaline, isoprenaline, and β3-AR agonists 4-(-{[2-hydroxy-(3-chlorophenyl)ethyl]-amino}propyl)phenoxyacetate (BRL 37,344) and (R,R)-5-(2-{[2-(3-chlorophenyl)-2-hydroxyethyl]-amino}propyl)-1,3-benzo-dioxole-2,2-dicarboxylate (CL 316,243) by testing their lipolytic action in white fat cells. Five mammalian species were studied: rat, hamster and dog, in which selective β3-AR agonists act as full lipolytic agents, and guinea-pigs and humans, in which β3-AR agonists are less potent activators of lipolysis.

Several biogenic amines were inefficient (e.g. dopamine, tyramine and β-phenylethylamine) while others (synephrine, phenylethanolamine, epinine) were partially active in stimulating lipolysis in all species studied. Their actions were inhibited by all the β-AR antagonists tested, including those selective for β1- or β2-ARs. Octopamine was the only amine fully stimulating lipolysis in rat, hamster and dog fat cells, while inefficient in guinea-pig or human fat cells, like the β3-AR agonists. In rat white fat cells, β-AR antagonists inhibited the lipolytic effect of octopamine with a relative order of potency very similar to that observed against CL 316,243. Competitive antagonism of octopamine effect resulted in the following apparent pA 2 [–log(IC50), where IC50 is the antagonist concentration eliciting half-maximal inhibition] values: 7.77 (bupranolol), 6.48 [3-(2-ethylphenoxy)-1[(1 S)-1,2,3,4-tetrahydronaphth-1-ylaminol]-(2S)2-propanol oxalate, SR 59230A, a β3-selective antagonist], 6.30 [erythro-d,l-1(7-lethylindan-4-yloxy)-3-isopropylamino-butan-2-ol, ICI 118,551, a β2-selective antagonist] and 4.71 [(±)-[2-(3-carbomyl-4-hydroxyphenoxy)-ethylamino]-3-[4-(1-methyl-4-trifluoromethyl-2-imi-dazolyl)-phenoxy]2-propanolmethane sulphonate, CGP 20712A, a β1-selective antagonist]. Octopamine had other properties in common with β3-AR agonists: stimulation of oxygen consumption in rat brown fat cells and very low affinity in displacing [3H]CGP 12,177 binding to β1- or β2-ARs in dog and rat adipocyte membranes. In Chinese hamster ovary (CHO) cells expressing human β3-ARs, octopamine inhibited [125I]ICYP binding with only twofold less affinity than noradrenaline while it exhibited an affinity around 200-fold lower than noradrenaline in CHO cells expressing human β1- or β2-ARs. These data suggest that, among the biogenic amines metabolically related to catecholamines, octopamine can be considered as the most selective for β3-ARs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 16 November 1998 / Accepted: 13 January 1999

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carpéné, C., Galitzky, J., Fontana, E. et al. Selective activation of β3-adrenoceptors by octopamine: comparative studies in mammalian fat cells. Naunyn-Schmiedeberg's Arch Pharmacol 359, 310–321 (1999). https://doi.org/10.1007/PL00005357

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/PL00005357

Navigation